ELEV Elevation Oncology, Inc.Stock Price & Overview
$3.51
Charts
Quant Ranking
ELEV Analysis
ELEV News
Latest Headlines
Ratings Summary
People Also Follow
Similar to ELEV
ETFs Holding ELEV
ELEV Company Profile
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company’s lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
ELEV Revenue
ELEV Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
ELEV Ownership
ELEV Peers
Risk
Technicals
Investor Presentations
ELEV SEC Filings
Press Releases
ELEV Income Statement
ELEV Balance Sheet
ELEV Cash Flow Statement
ELEV Long Term Solvency
Discover More
You may be interested in: